Skip to main content

Table 2 Baseline characteristics for patients in the development and validation cohorts according to non-achievement of remission

From: Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort

q

Nordic development cohort (N = 427)

ReACCh-Out validation cohort (N = 506)

Remission (n = 181)

Non-remission (n = 246)

Remission (n = 98)

Non-remission (n = 408)

Characteristics

 Age at onset, years

5.9 (2.5, 10.0)*

5.2 (2.5, 9.5)

8.0 (3.6, 11.5)

7.2 (2.6, 11.1)

 Female, n (%)

115 (63.5)

169 (68.7)

62 (63.3)

285 (70.4)

 Onset to enrolment, months

7 (6, 8)

6.5 (6, 8)

3.9 (2.4, 6.0)

5.1 (2.7, 9.7)

JIA category, n (%)**

 Oligoarthritis

107 (59.1)

111 (45.1)

55 (56.1)

137 (33.6)

 RF-neg. polyarthritis

25 (13.8)

68 (27.6)

4 (4.1)

113 (27.7)

 RF-pos. polyarthritis

1 (0.6)

3 (1.2)

0 (0.0)

17 (4.2)

 Systemic

15 (8.3)

2 (0.8)

13 (13.3)

28 (6.9)

 Enthesitis-related

11 (6.1)

23 (9.3)

8 (8.2)

50 (12.3)

 Psoriatic

3 (1.7)

3 (1.2)

8 (8.2)

20 (4.9)

 Undifferentiated

19 (10.5)

36 (14.6)

10 (10.2)

43 (10.5)

Assessments and laboratory tests

Active joints, n (%)

 Cervical arthritis

13 (7.2)

25 (10.2)

0 (0.0)

26 (7.0)

 Finger arthritis

40 (22.1)

94 (38.2)

16 (19.3)

167 (44.7)

 Ankle arthritis

65 (35.9)

129 (52.4)

17 (20.5)

186 (49.7)

 Hip arthritis

24 (13.3)

38 (15.4)

7 (8.4)

50 (13.4)

 Active joint count***

2 (1, 4)

4 (2, 7)

1 (1, 2)

3 (1, 9)

 Physician global assessment

0.8 (0.0, 1.3)

2.0 (1.0, 3.8)

1.9 (1.0, 3.2)

3.8 (2.0, 6.0)

 Parent global assessment

0.6 (0.0, 2.0)

1.7 (0.5, 3.5)

0.7 (0.2, 2.4)

2.3 (0.7, 4.9)

 Pain

0.4 (0.0, 3.0)

2.3 (0.5, 4.2)

1.0 (0.2, 3.0)

3.9 (1.0, 6.1)

 CHAQ DI

0.1 (0.0, 0.6)

0.5 (0.0, 1.1)

0.1 (0.0, 0.5)

0.5 (0.1, 1.1)

 Stiffness > 15 min (%)

30 (16.6)

90 (36.6)

45 (55.6)

184 (65.0)

 ESR****

11.5 (6, 20)

17.5 (10, 31)

20 (9, 34)

21 (9, 40)

 CRP****

0.0 (0, 0)

0.0 (0, 15)

2.0 (0.2, 10)

3.0 (0.3, 17)

 ANA

37 (20.4)

76 (30.9)

49 (50.0)

182 (50.7)

 RF

5 (2.8)

5 (2.0)

5 (5.1)

23 (6.4)

 HLA B27

22 (12.2)

60 (24.4)

5 (5.1)

36 (10.0)

Treatment by first study visit (%)

 NSAIDs

152 (84.0)

215 (87.4)

88 (89.8)

390 (95.6)

 Joint injections

84 (46.4)

152 (61.8)

24 (24.5)

88 (21.6)

 DMARDs

20 (11.0)

71 (28.9)

9 (9.2)

137 (33.6)

 Biologics

0

0

1 (1)

1 (0.2)

  1. *Numbers are median (25th centile, 75th centile) or number of patients (%)
  2. **Patients with systemic JIA were excluded from the Nordic prediction model development study. They are included in the validation cohort and in this table
  3. ***The Nordic development cohort used the cumulative active joint count within 6 months of disease onset, and the ReACCh-Out validation cohort used the active joint count at baseline
  4. ****Erythrocyte sedimentation rate measurements were available for 322 of 427 patients (75.4%) in the Nordic cohort and for 458 of 506 patients (90.5%) in the ReACCh-Out cohort. C-reactive protein measurements were available for 345 of 427 patients (80.8%) in the Nordic cohort and 404 of 506 patients (79.8%) in the ReACCh-Out cohort